Iovance Biotherapeutics (NASDAQ:IOVA) and Atara Biotherapeutics (NASDAQ:ATRA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.
Profitability
This table compares Iovance Biotherapeutics and Atara Biotherapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Iovance Biotherapeutics | N/A | -50.64% | -45.64% |
| Atara Biotherapeutics | N/A | -94.86% | -82.17% |
Analyst Ratings
This is a summary of recent recommendations and price targets for Iovance Biotherapeutics and Atara Biotherapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Iovance Biotherapeutics | 0 | 2 | 8 | 0 | 2.80 |
| Atara Biotherapeutics | 0 | 3 | 7 | 0 | 2.70 |
Iovance Biotherapeutics presently has a consensus target price of $50.10, suggesting a potential upside of 54.82%. Atara Biotherapeutics has a consensus target price of $35.8750, suggesting a potential upside of 123.24%. Given Atara Biotherapeutics' higher possible upside, analysts plainly believe Atara Biotherapeutics is more favorable than Iovance Biotherapeutics.
Insider and Institutional Ownership
94.6% of Iovance Biotherapeutics shares are held by institutional investors. 9.9% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 4.3% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Iovance Biotherapeutics and Atara Biotherapeutics' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Iovance Biotherapeutics | N/A | N/A | $-197,560,000.00 | ($1.59) | -20.35 |
| Atara Biotherapeutics | N/A | N/A | $-290,980,000.00 | ($5.67) | -2.83 |
Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Iovance Biotherapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 2.65, indicating that its share price is 165% more volatile than the S&P 500.
Summary
Iovance Biotherapeutics beats Atara Biotherapeutics on 8 of the 11 factors compared between the two stocks.
